Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.
Glucagon-like peptide 1 receptor agonists
Heart failure
Metformin
Sodium-glucose cotransporter 2 inhibitors
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
11
01
2022
received:
07
10
2021
accepted:
16
01
2022
pubmed:
30
1
2022
medline:
26
3
2022
entrez:
29
1
2022
Statut:
ppublish
Résumé
The cardioprotective effects of glucose-lowering medications in diabetic patients with heart failure (HF) are well known. Several large randomized controlled trials (RCTs) have recently suggested that the cardioprotective effects of glucose-lowering medications extend to HF patients regardless of diabetic status. The aim of this study was to conduct a Bayesian network meta-analysis to evaluate the impact of various glucose-lowering medications on the outcomes of non-diabetic HF patients. Medline and Embase were searched for RCTs investigating the use of glucose-lowering medications in non-diabetic HF patients in August 2021. Studies were included in accordance with the inclusion and exclusion criteria, and data were extracted with a pre-defined datasheet. Primary outcomes include serum N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, left ventricular ejection fraction (LVEF), and maximal oxygen consumption (PVO This Bayesian network meta-analysis demonstrated that SGLT2i, when compared with GLP1-RA and metformin, was superior in improving LVEF in HF with reduced ejection fraction patients, as well as improving PVO
Identifiants
pubmed: 35092176
doi: 10.1002/ehf2.13822
pmc: PMC8934935
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1338-1350Informations de copyright
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Cardiovasc Diabetol. 2019 Aug 28;18(1):112
pubmed: 31462224
Cardiovasc Drugs Ther. 2018 Feb;32(1):65-72
pubmed: 29445896
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
JACC Heart Fail. 2016 Jul;4(7):559-566
pubmed: 27039125
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
BMJ Open. 2014 Apr 19;4(4):e004675
pubmed: 24747793
Eur Heart J. 2021 Dec 21;42(48):4901
pubmed: 34649282
Eur J Heart Fail. 2019 May;21(5):665-675
pubmed: 30895697
N Engl J Med. 2016 Mar 17;374(11):1094
pubmed: 26981940
Circ Res. 2018 May 11;122(10):1439-1459
pubmed: 29748368
Diabetes. 2016 May;65(5):1190-5
pubmed: 26861783
Eur Heart J. 2003 Oct;24(19):1735-43
pubmed: 14522568
J Clin Endocrinol Metab. 2016 Jan;101(1):157-66
pubmed: 26580237
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2021 Oct 14;385(16):1522-1524
pubmed: 34449180
Endocrine. 2021 Jun;72(3):699-710
pubmed: 33830437
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
ESC Heart Fail. 2022 Apr;9(2):1338-1350
pubmed: 35092176
Eur Heart J. 2020 Sep 14;41(35):3346-3358
pubmed: 32077924
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Medicine (Baltimore). 2018 Oct;97(43):e12843
pubmed: 30412076
JAMA. 2020 Apr 14;323(14):1353-1368
pubmed: 32219386
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
Ther Apher Dial. 2015 Dec;19(6):598-605
pubmed: 26556397
J Am Coll Cardiol. 2003 Aug 20;42(4):736-42
pubmed: 12932612
JACC Heart Fail. 2016 Aug;4(8):607-16
pubmed: 27289406
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Diabetes Metab Res Rev. 2019 Feb;35(2):e3100
pubmed: 30467957
Eur J Heart Fail. 2017 Jan;19(1):69-77
pubmed: 27790809
Circ Heart Fail. 2016 Jan;9(1):
pubmed: 26754626
Diabetes Care. 2016 Jul;39(7):1115-22
pubmed: 27289124
Front Cardiovasc Med. 2021 Jun 30;8:690529
pubmed: 34277737
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
JAMA. 2016 Aug 2;316(5):500-8
pubmed: 27483064
Res Synth Methods. 2012 Dec;3(4):285-99
pubmed: 26053422
BMC Med Res Methodol. 2019 Oct 22;19(1):196
pubmed: 31640567
Front Endocrinol (Lausanne). 2021 Apr 09;12:609110
pubmed: 33897616
Endocrine. 2017 Sep;57(3):464-473
pubmed: 27830456
Diabetes Care. 2018 Feb;41(2):356-363
pubmed: 29203583
Cardiovasc Diabetol. 2020 Jan 22;19(1):10
pubmed: 31969144
BMJ Open. 2019 Feb 1;9(1):e022577
pubmed: 30813108
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23
pubmed: 31081589
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Diabetes Obes Metab. 2018 Mar;20(3):479-487
pubmed: 29024278
Lancet. 2021 Jul 17;398(10296):262-276
pubmed: 34216571
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
Circulation. 2005 Dec 13;112(24):3738-44
pubmed: 16330684
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:30-39
pubmed: 34324260
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255
pubmed: 33197559
Prim Care Diabetes. 2019 Jun;13(3):204-211
pubmed: 30713085
Eur J Heart Fail. 2020 Sep;22(9):1628-1637
pubmed: 31863557
J Nucl Cardiol. 2019 Apr;26(2):585-597
pubmed: 28770459
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662
pubmed: 34425083
J Clin Endocrinol Metab. 2021 Sep 27;106(10):3060-3067
pubmed: 34125217
N Engl J Med. 2021 Sep 2;385(10):896-907
pubmed: 34215025
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):545-549
pubmed: 28948430
Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1096-102
pubmed: 20081109
Diabetes Res Clin Pract. 2018 Jun;140:118-128
pubmed: 29604389
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227